Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Colorectal Neoplasms, Metastases, Neoplasm

In brief

The purpose of this study is to assess the Safety, Tolerability and Efficacy of ZD6126 in Combination with Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects with Metastatic Colorectal Cancer.

Key facts

Study ID

NCT00065117

Run by

AstraZeneca

People needed

180

Starts

2003-09-01

Expected to finish

2004-02-01

Last updated by the study team

2011-01-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic colorectal carcinoma
• Suitable for first-line treatment of metastatic disease

You may not qualify if…

• Peripheral neuropathy greater than Grade 1
• Adjuvant therapy within 6 months prior to study treatment
• Prior oxaliplatin
• Prior pelvic or whole abdomen radiation
• Any history of coronary angioplasty or history of myocardial infarction

Where it is running

• Research Site — Los Angeles, California, United States
• Research Site — San Francisco, California, United States
• Research Site — Chicago, Illinois, United States
• Research Site — New Orleans, Louisiana, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — St Louis, Missouri, United States
• Research Site — New York, New York, United States
• Research Site — Chapel Hill, North Carolina, United States
• Research Site — Durham, North Carolina, United States
• Research Site — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.